Clinical Trial

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-01.
Trial Details
NCT Number NCT06540261
Lead Sponsor Ono Pharmaceutical Co., Ltd.
Conditions Unresectable Colorectal Cancer
Enrollment 65 participants
Start Date 2021-09-23
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19